ES2464777T3 - Método de producción de proteína TAT-HOXB4H recombinante para su utilización como estimulante de la hematopoyesis in vivo - Google Patents

Método de producción de proteína TAT-HOXB4H recombinante para su utilización como estimulante de la hematopoyesis in vivo Download PDF

Info

Publication number
ES2464777T3
ES2464777T3 ES08153854.8T ES08153854T ES2464777T3 ES 2464777 T3 ES2464777 T3 ES 2464777T3 ES 08153854 T ES08153854 T ES 08153854T ES 2464777 T3 ES2464777 T3 ES 2464777T3
Authority
ES
Spain
Prior art keywords
protein
solution
column
tat
hoxb4h
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES08153854.8T
Other languages
English (en)
Inventor
Kou-Juey Wu
Chi-Hung Huang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
TAIWAN ADVANCE BIO-PHARM Inc
Taiwan Advance Bio Pharm Inc
Original Assignee
TAIWAN ADVANCE BIO-PHARM Inc
Taiwan Advance Bio Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by TAIWAN ADVANCE BIO-PHARM Inc, Taiwan Advance Bio Pharm Inc filed Critical TAIWAN ADVANCE BIO-PHARM Inc
Application granted granted Critical
Publication of ES2464777T3 publication Critical patent/ES2464777T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Water Supply & Treatment (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Un metodo de produccion de una proteina TAT-HOXB4H que comprende: (a) proporcionar una celula huesped que comprende un vector que codifica la proteina de fusion TAT-HOXB4 etiquetada con histidina de terminal C (TAT-HOXB4H) que contiene por lo menos 6 residuos de histidina en el terminal C; (b) expresar la proteina en la celula huesped; (c) recoger una solucion impura de la proteina expresada; (d) purificar la proteina de la solucion mediante: (i) aplicar la solucion a una columna de HisTrap; (ii) lavar la columna de la HisTrap; (iii) eluir la proteina parcialmente purificada de la columna de HisTrap para formar una solucion de proteina parcialmente purificada; (iv) la aplicacion de la solucion de proteina parcialmente purificada a una columna de MonoSP; (v) lavar la columna de la MonoSP; (vi) eluir la proteina purificada a partir de la columna de la MonoSP en forma desnaturalizada; (e) el replegamiento de la proteina desnaturalizada eluida utilizando compuestos hidrofobos mediante.

Claims (1)

  1. REIVINDICACIONES
ES08153854.8T 2008-03-04 2008-03-31 Método de producción de proteína TAT-HOXB4H recombinante para su utilización como estimulante de la hematopoyesis in vivo Active ES2464777T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42097 2008-03-04
US12/042,097 US8222206B2 (en) 2008-03-04 2008-03-04 Method of enhancing the mobilization of hematopoietic stem cells using TAT-HOXB4H

Publications (1)

Publication Number Publication Date
ES2464777T3 true ES2464777T3 (es) 2014-06-04

Family

ID=40627112

Family Applications (2)

Application Number Title Priority Date Filing Date
ES08153854.8T Active ES2464777T3 (es) 2008-03-04 2008-03-31 Método de producción de proteína TAT-HOXB4H recombinante para su utilización como estimulante de la hematopoyesis in vivo
ES12152269.2T Active ES2567780T3 (es) 2008-03-04 2008-03-31 Método para la producción de proteína TAT-HOXB4H recombinante para su utilización como estimulante de la hematopoyesis in vivo

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES12152269.2T Active ES2567780T3 (es) 2008-03-04 2008-03-31 Método para la producción de proteína TAT-HOXB4H recombinante para su utilización como estimulante de la hematopoyesis in vivo

Country Status (15)

Country Link
US (4) US8222206B2 (es)
EP (2) EP2455099B1 (es)
JP (2) JP4755224B2 (es)
KR (1) KR101160381B1 (es)
CN (3) CN101524527B (es)
BR (1) BRPI0803381A2 (es)
CA (1) CA2658231C (es)
ES (2) ES2464777T3 (es)
HK (2) HK1130290A1 (es)
HU (1) HUE027513T2 (es)
MY (1) MY164521A (es)
PL (2) PL2100968T3 (es)
PT (1) PT2100968E (es)
RU (1) RU2401863C2 (es)
TW (1) TWI414598B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8222206B2 (en) * 2008-03-04 2012-07-17 Taiwan Advance Bio-Pharm Inc. Method of enhancing the mobilization of hematopoietic stem cells using TAT-HOXB4H
US10896327B1 (en) 2013-03-15 2021-01-19 Spatial Cam Llc Device with a camera for locating hidden object
US10354407B2 (en) 2013-03-15 2019-07-16 Spatial Cam Llc Camera for locating hidden objects
EP2689008B1 (en) * 2011-03-22 2017-09-27 Pluristem Ltd. Methods for treating radiation or chemical injury
RU2495125C2 (ru) * 2011-12-07 2013-10-10 Федеральное государственное бюджетное учреждение "Новосибирский научно-исследовательский институт патологии кровообращения имени академика Е.Н. Мешалкина" Министерства здравоохранения Российской Федерации (ФГБУ "ННИИПК им. акад. Е.Н. Мешалкина" Минздрава России) РЕКОМБИНАНТНАЯ ПЛАЗМИДА pOK-DsRed2, КОДИРУЮЩАЯ БЕЛКИ ОСТ4 И KLF4 ЧЕЛОВЕКА И ФЛУОРЕСЦЕНТНЫЙ БЕЛОК DsRed2, ПРЕДНАЗНАЧЕНАЯ ДЛЯ ПОЛУЧЕНИЯ ИНДУЦИРОВАННЫХ ПЛЮРИПОТЕНТНЫХ СТВОЛОВЫХ КЛЕТОК ЧЕЛОВЕКА
US9783783B2 (en) * 2013-01-30 2017-10-10 Cornell University Compositions and methods for the expansion of stem cells
CA2908739A1 (en) * 2013-04-05 2014-10-09 Claudia Zylberberg Matrix metalloproteinases and uses thereof
TWI548748B (zh) * 2015-04-16 2016-09-11 台灣尖端先進生技醫藥股份有限公司 造血幹／先驅細胞之體外放大培養方法及其立即可使用之組成物
US11564942B2 (en) 2016-02-19 2023-01-31 The General Hospital Corporation Methods for generating universal and custom MHC/HLA-compatible hematopoietic progenitor cells
KR102641343B1 (ko) 2018-09-24 2024-02-27 보스톤 싸이엔티픽 싸이메드 인코포레이티드 조직 보유력이 개선된 공격적인 특징의 클립
TW202026307A (zh) * 2019-01-11 2020-07-16 台灣尖端先進生技醫藥股份有限公司 Ｎ－端標記組胺酸之重組ｔａｔ－ｈｏｘ家族蛋白質及其製造方法
TWI756518B (zh) * 2019-02-27 2022-03-01 台灣尖端先進生技醫藥股份有限公司 突變型ｈｏｘｂ４重組蛋白質之製造方法與用途

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2838867B2 (ja) * 1986-01-22 1998-12-16 中外製薬株式会社 幹細胞増殖促進剤
JPH0276820A (ja) * 1988-06-15 1990-03-16 Ajinomoto Co Inc 骨髄移植療法支持剤
JPH06133780A (ja) * 1992-10-23 1994-05-17 Sumitomo Pharmaceut Co Ltd 新規なｔ−ＰＡ改変体
US5837507A (en) * 1995-11-13 1998-11-17 The Regents Of The University Of California Hox-induced enhancement of in vivo and in vitro proliferative capacity and gene therapeutic methods
US6303337B1 (en) * 1999-08-25 2001-10-16 Amber Gen. Inc. N-terminal and C-terminal markers in nascent proteins
US20040072298A1 (en) * 2000-02-23 2004-04-15 Guy Sauvageau Stem cell expansion enhancing factor and method of use
US20040082003A1 (en) * 2000-02-23 2004-04-29 Guy Sauvageau Stem cell expansion enhancing factor and method of use
US20020086383A1 (en) * 2000-02-23 2002-07-04 Guy Sauvageau Hematopoietic stem cell expansion enhancing factor and method of use
DE10050935A1 (de) * 2000-10-11 2002-05-02 Tegenero Gmbh Verwendung CD28 spezifischer monoklonaler Antikörper zur Stimulation von Blutzellen, welche kein CD28 tragen
CA2489410C (en) * 2002-07-17 2015-01-13 Cytos Biotechnology Ag Molecular antigen arrays
US20060121566A1 (en) * 2002-10-08 2006-06-08 Institute De Recherches Cliniques De Montreal Stem cell expansion factor blocking gene limiting hox-induced expansion and method using such factor
US20040229330A1 (en) 2003-02-27 2004-11-18 Bayer Pharmaceuticals Corporation Integrated method for capture and purification of tagged proteins
WO2005007093A2 (en) * 2003-07-03 2005-01-27 University Of Southern California Uses of il-12 in hematopoiesis
WO2005026196A2 (en) 2003-09-12 2005-03-24 Novexin Limited Methods for folding proteins and reducing protein aggregation
TW200517398A (en) 2003-11-21 2005-06-01 Ind Tech Res Inst Method for recombinant protein purification, modification and immobilization
US20080299095A1 (en) * 2004-07-09 2008-12-04 Bc Cancer Agency Nup98-Hox Fusions for Expansion of Hemopoietic Stem Cells
TWI328036B (en) * 2005-07-01 2010-08-01 Taiwan Advance Bio Pharm Inc Process for producing c-termial histidine tagged hoxb4 and the use thereof in expanding stem cells
CN101016540B (zh) 2006-02-10 2010-04-07 台湾尖端先进生技医药股份有限公司 C-端含有组氨酸标记的hoxb4重组蛋白质的制造方法及用途
EP2377924A1 (en) * 2006-04-14 2011-10-19 Advanced Cell Technology, Inc. Hemangio-colony forming cells
TWI311562B (en) 2006-05-09 2009-07-01 Northern Taiwan Bio Pharm Inc One step rapid desalting and protein refolding process
TWI369990B (en) 2006-09-05 2012-08-11 Taiwan Advance Bio Pharminc Hsc proliferated with c-histidine labeled hoxb4h and use thereof
US8222206B2 (en) * 2008-03-04 2012-07-17 Taiwan Advance Bio-Pharm Inc. Method of enhancing the mobilization of hematopoietic stem cells using TAT-HOXB4H

Also Published As

Publication number Publication date
JP2009207482A (ja) 2009-09-17
RU2008134247A (ru) 2010-02-27
US8450458B2 (en) 2013-05-28
EP2100968B1 (en) 2014-02-26
EP2100968A1 (en) 2009-09-16
US20120322979A1 (en) 2012-12-20
HK1130290A1 (en) 2009-12-24
ES2567780T3 (es) 2016-04-26
PL2100968T3 (pl) 2014-08-29
KR101160381B1 (ko) 2012-06-26
CN104650210A (zh) 2015-05-27
CN101524527A (zh) 2009-09-09
JP4755224B2 (ja) 2011-08-24
KR20090095473A (ko) 2009-09-09
CA2658231A1 (en) 2009-09-04
US8222207B2 (en) 2012-07-17
PL2455099T3 (pl) 2016-07-29
US20110092450A1 (en) 2011-04-21
CN102805859B (zh) 2016-06-01
MY164521A (en) 2017-12-29
TW200938632A (en) 2009-09-16
US8124377B2 (en) 2012-02-28
RU2401863C2 (ru) 2010-10-20
PT2100968E (pt) 2014-05-30
BRPI0803381A2 (pt) 2011-08-23
CN101524527B (zh) 2016-06-01
JP2011168597A (ja) 2011-09-01
US20090227496A1 (en) 2009-09-10
CN104650210B (zh) 2018-01-23
EP2455099B1 (en) 2016-01-20
HK1170933A1 (zh) 2013-03-15
CN102805859A (zh) 2012-12-05
EP2455099A1 (en) 2012-05-23
US20110092412A1 (en) 2011-04-21
TWI414598B (zh) 2013-11-11
CA2658231C (en) 2014-09-23
HUE027513T2 (en) 2016-10-28
US8222206B2 (en) 2012-07-17
JP5738636B2 (ja) 2015-06-24

Similar Documents

Publication Publication Date Title
ES2464777T3 (es) Método de producción de proteína TAT-HOXB4H recombinante para su utilización como estimulante de la hematopoyesis in vivo
AR091647A1 (es) Purificacion de iduronato-2-sulfatasa
CL2011003122A1 (es) Anticuerpo que se une a la proteina tau fosforilada en la serina 422 (tau ps422), pero no se une a la tau ni al fragmento mcak fosforilado; acido nucleico que lo codifica; metodo de produccion; composicion farmaceutica; y uso util en el tratamiento de una tauopatia, tal como la enfermedad de alzheimer.
AR074015A1 (es) Purificacion de proteinas acidas utilizando cromatografia de hidroxiapatita ceramica
RU2012108039A (ru) Хроматографические способы и соединения, очищенные этими способами
CL2011000769A1 (es) Anticuerpo biespecifico que se une especificamente al factor de crecimiento endotelial vascular humano (vegf) y a la angiopoyetina-2 humana (ang-2); acido nucleico que lo codifica; vector de expresion recombinante; celula hospedadora; metodo de produccion del anticuerpo; composicion farmaceutica que lo comprende; y su uso para tratar el cancer.
UA100901C2 (ru) Способ очищения фактора свертывания крови viii
AR070119A1 (es) Derivados de insulina con perfil tiempo / accion extremadamente retardado
IL220164B (en) A method for purifying a purified antibody, antibody fragment, or fc-fused protein using an affinity chromatography matrix
EA201190326A8 (ru) Полипептиды гормона роста и способы их получения и применения
BR112014012275A2 (pt) purificação de proteína com a utilização de tampão bis-tris
AR069097A1 (es) Purificacion de anticuerpos por cromatografia de intercambio cationico
CL2007001840A1 (es) Anticuerpo neutralizante que se une a la interleuquina 17 humana (il-17); secuencia de adn que lo codifica; vector y celula huesped que la comprenden; proceso de produccion; preparacion farmaceutica que lo comprende; y su uso para el tratamiento o profilaxis de patologias mediadas por il-17.
PE20091352A1 (es) Composicion que comprende anticuerpo que se fija al dominio ii de her2, y sus variantes acidas
EA201691109A1 (ru) Химерные и гибридные полипептиды фактора viii-fc и способы их применения
CY1112323T1 (el) Παραγωγη και καθαρισμος της il-29
EA200970231A1 (ru) СПОСОБ ОЧИСТКИ Fc-СОДЕРЖАЩИХ БЕЛКОВ
EA201590545A1 (ru) Полипептиды, содержащие fc с измененным гликозилированием и сниженной эффекторной функцией
BR112012011305A2 (pt) uso de uma proteína homóloga a uma proteína meab para aumentar a atividade enzimática de uma mutase do ácido 3-hidroxicarboxílico-coa
AR088252A1 (es) Produccion de una proteina de interes mediante un promotor regulable de pichia pastoris
CL2009000210A1 (es) Acidos nucleicos que comprenden una secuencia que codifica un peptido de transito a plastidios de una glaucosafita enlazada a una segunda secuencia que codifica un peptido heterologo; metodo para la expresion estable de un polipeptido heterologo en una planta; polipeptido aislado codificado por el acido nucleico descrito anteriormente.
BRPI0713252C1 (pt) processo para a recuperação de fator de crescimento endotelial vascular (vegf) recombinante reenovelado
CR10591A (es) Metodo para la produccion de conjugados del factor de crecimiento similar a la insulina-1 y polietilenglicol
CL2013000475A1 (es) Polipeptidos de relaxina que comprende uno o mas aminoacidos codificados no naturales; acido nucleico aislado; metodo para preparar el polipeptido de relaxina.
ECSP12011577A (es) Produccion recombinante de péptidos